Professor Chris Denton: Ledger

Stories naming Professor Chris Denton. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Role	Organisation	Sources
Professor of Experimental Rheumatology	University College London	Brandon Capital, Brandon BioCatalyst

News

Certa Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma

Melbourne biotech Certa Therapeutics reported encouraging Phase 2 results for its scleroderma drug FT011 at a US rheumatology meeting, with safety confirmed and a pivotal trial planned.

Brandon Capital portfolio 16 Nov 2023 CERTA TherapeuticsTreatment of fibrotic diseases EMA University College London University of Michigan US Food and Drug Administration Professor Chris Denton Professor Darren Kelly Professor Dinesh Khanna

Professor Chris Denton

Roles

Coverage

Certa Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma

Certa Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma